Knockout of TRIM22 in GBM#P3 cells led to decreased tumor growth in vivo (Fig. 7d, e) and prolonged the survival time of tumor-bearing mice (GBM#P3: 44 or 47 days vs. 34 days, sg-TRIM22-1 or -2 vs. sg-scramble, respectively, P < 0.05; BG5: 55 or 52 days vs. 35 days, sg-TRIM22-1 or -2 vs. sg-scramble, respectively, P < 0.05; Fig. 7f). The gene discussed is TRIM22; the disease is neoplasm.